logo-loader
Keystone Bio

Keystone Bio has 'many avenues' to take its heart disease drug to a larger stage

Peter Nara, CEO of Keystone Bio speaks to Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

Keystone Bio is initiating Phase I/II clinical trials for its proprietary bio-therapeutic-drug for heart disease targeting volatile coronary artery plaque and post-event myocardium vulnerability.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks flat but Valens shares on the rise as it...

Buds today are Valens GroWorks Corp (CVE:VGW) (OTCMKTS:VGWCF), The Flowr Corporation (CVE:FLWR) (OTCMKTS:FLWPF).  Duds are CannTrust Holdings Inc (TSE:TRST) (NYSE:CTST), Canopy Growth Corporation (TSE:WEED) (NYSE:CGC). 

25 minutes ago

2 min read